[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Aryeh Jason, a director of Orchestra BioMed Holdings, Inc. (OBIO), was awarded 15,000 restricted stock units (RSUs) on 08/07/2025. Each RSU represents a contingent right to receive one share of common stock, and the filing shows the reporting person beneficially owns 107,482 shares following the award.

The RSUs are scheduled to vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service through that date. The transaction is reported as a non-derivative equity award (Transaction Code A) with a reported price of $0 and is held in a direct ownership form.

Insights

Corporate Governance Expert

TL;DR: Director equity award aligns management and shareholder interests; routine, non-derivative, and administratively standard.

The Form 4 documents a standard director compensation event: an award of 15,000 RSUs that convert into common shares upon vesting. Vesting is time-based (one year) and conditioned on continuous service, which is a common retention mechanism. The filing shows direct beneficial ownership of 107,482 shares post-award and no derivative transactions are reported. From a governance standpoint, this is a routine alignment tool rather than an unusual corporate action.

Securities Analyst

TL;DR: Non-derivative RSU grant reported; transaction code A and price $0 indicate a standard equity award with limited immediate market impact.

The entry is recorded as an acquisition (Transaction Code A) of 15,000 RSUs at a reported price of $0, reflecting a compensation grant rather than an open-market purchase. The RSUs vest in one year and are reported as direct holdings, increasing the reporting person’s total to 107,482 shares. The Form 4 lists no derivative positions or sales tied to this transaction, suggesting no immediate change in liquidity or selling pressure from this award alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aryeh Jason

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/07/2025		A		15,000(1)	A	$0	107,482	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.

	/s/ Andrew Taylor, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did OBIO report on this Form 4?

The Form 4 reports an award of 15,000 restricted stock units (RSUs) to the reporting person on 08/07/2025.

Who is the reporting person on the OBIO Form 4?

The reporting person is Aryeh Jason, listed as a Director of Orchestra BioMed Holdings, Inc. (OBIO).

How many shares does the reporting person beneficially own after the transaction?

The Form 4 shows the reporting person beneficially owns 107,482 shares following the reported RSU award.

What is the RSU vesting schedule reported in the Form 4?

The RSUs will vest on the one-year anniversary of the grant date, subject to the reporting person’s continuous service through that date.

Was the RSU grant reported as part of a Rule 10b5-1 trading plan?

The Form 4 does not indicate that this transaction was made pursuant to a Rule 10b5-1 trading plan.

What transaction code and price are reported for the award?

The award is reported with Transaction Code A (acquisition/award) and a reported price of $0.